4 of the Top 7 Global CROs Have Selected Veeva Vault eTMF as Their Enterprise Standard

PLEASANTON, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/clinical?src=hash” target=”_blank”gt;#clinicallt;/agt;–Veeva
Systems
(NYSE:VEEV) today announced four of the world’s top seven
largest CROs are standardizing on Veeva
Vault eTMF
. These leading CROs have selected Vault eTMF to improve
trial efficiency, give sponsors full visibility into TMF status, and
ensure their TMFs are always inspection ready.

“CROs are taking steps to modernize their clinical operations to drive
more efficient trials,” said Jim Reilly, vice president of Veeva
Vault Clinical
. “Our goal is to make it easier for CROs to work with
sponsors and sites and accelerate drug development. We’re honored to
support CROs’ mission to speed study execution and get treatments to
patients faster.”

CROs are adopting Vault eTMF to improve operational performance and
deliver greater transparency into TMF quality. Vault eTMF manages all
TMF documents and processes in one system, in real-time, as they are
executed. This active TMF operating model enables CROs to maintain an
always up-to-date TMF and gives sponsors greater control of standard
operating procedures for TMF management.

Additional Information

For more information on Veeva Vault eTMF, visit: veeva.com/eTMF

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

Follow @veevasystems on Twitter: twitter.com/veevasystems

Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Vault Clinical Suite

Veeva Vault eTMF is part of the Veeva Vault Clinical Suite, the
industry’s first cloud platform that includes CDMS, CTMS, eTMF, and
study start-up to unify clinical data management and clinical
operations. Veeva’s suite of unified applications provides global
visibility into trial activities and streamlines end-to-end clinical
processes. For more information, visit veeva.com/Clinical.

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 675 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices throughout
North America, Europe, Asia, and Latin America. For more information,
visit veeva.com.

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended October 31, 2018. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.

Contacts

Roger Villareal
Veeva Systems
925-264-8885
[email protected]

Lisa Barbadora
Veeva Systems
610-420-3413
[email protected]

error: Content is protected !!